Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
Recruiting · NCT05742425 · Registry updated 2023-02-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases | PMMR/Ras/BRAF Wild-type; Unresectable Colon Cancer Peritoneal Metastases | Recruiting | Phase 2 | 2023-02-24 | NCT05742425 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Changxing People's Hospital | 7 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 561 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Changxing County People's Hospital | Huzhou | China | 1 |